Skip to main content

Landmark Vertex cystic fibrosis drug could hit market by late 2019: analyst

The Boston-based company said Wednesday that the FDA would allow it to conduct a faster-than-expected study of the “triple combination” treatment.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.